Barings LLC continued to hold its stake in shares of Core Laboratories N.V. (NYSE:CLB) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,167 shares of the oil and gas company’s stock at the close of the 2nd quarter. Barings LLC’s holdings in Core Laboratories N.V. were worth $943,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in the stock. Callahan Advisors LLC raised its holdings in shares of Core Laboratories N.V. by 2.5% during the second quarter. Callahan Advisors LLC now owns 2,075 shares of the oil and gas company’s stock worth $210,000 after acquiring an additional 50 shares in the last quarter. Laurel Wealth Advisors Inc. raised its holdings in shares of Core Laboratories N.V. by 3.2% during the first quarter. Laurel Wealth Advisors Inc. now owns 2,071 shares of the oil and gas company’s stock worth $239,000 after acquiring an additional 65 shares in the last quarter. First Bank & Trust raised its holdings in shares of Core Laboratories N.V. by 5.8% during the second quarter. First Bank & Trust now owns 1,493 shares of the oil and gas company’s stock worth $152,000 after acquiring an additional 82 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Core Laboratories N.V. by 2.3% during the second quarter. ProShare Advisors LLC now owns 3,889 shares of the oil and gas company’s stock worth $394,000 after acquiring an additional 87 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Core Laboratories N.V. by 0.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,977 shares of the oil and gas company’s stock worth $1,112,000 after acquiring an additional 98 shares in the last quarter.
Core Laboratories N.V. (NYSE:CLB) last issued its quarterly earnings results on Monday, July 24th. The oil and gas company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.51 by $0.01. Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. The firm had revenue of $163.90 million for the quarter, compared to analysts’ expectations of $168.23 million. During the same period in the previous year, the firm posted $0.35 EPS. The company’s revenue for the quarter was up 10.7% on a year-over-year basis.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, November 21st. Shareholders of record on Friday, October 20th will be given a dividend of $0.55 per share. The ex-dividend date is Thursday, October 19th. This represents a $2.20 annualized dividend and a yield of 2.32%. Core Laboratories N.V.’s dividend payout ratio (DPR) is presently 134.15%.
ILLEGAL ACTIVITY WARNING: “Barings LLC Has $943,000 Holdings in Core Laboratories N.V. (CLB)” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://sportsperspectives.com/2017/10/13/barings-llc-has-943000-holdings-in-core-laboratories-n-v-clb.html.
CLB has been the topic of several recent research reports. Royal Bank Of Canada set a $145.00 target price on Core Laboratories N.V. and gave the company a “buy” rating in a report on Saturday, June 17th. Zacks Investment Research lowered Core Laboratories N.V. from a “hold” rating to a “strong sell” rating in a report on Monday, July 17th. Morgan Stanley restated an “overweight” rating and set a $130.00 target price (down from $150.00) on shares of Core Laboratories N.V. in a report on Wednesday, June 21st. BidaskClub upgraded Core Laboratories N.V. from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, ValuEngine upgraded Core Laboratories N.V. from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company’s stock. Core Laboratories N.V. has a consensus rating of “Hold” and a consensus target price of $110.91.
Core Laboratories N.V. Profile
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.